세계의 산소 농축기 시장 : 유형별, 기술별, 유량별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

The oxygen concentrators market is projected to reach USD 1.71 billion by 2030 from USD 1.27 billion in 2025, at a CAGR of 6.1% during the forecast period.

Technological advancements are crucial in driving growth in the oxygen concentrators market. Modern units are more compact, lightweight, energy-efficient, and user-friendly. Innovations like pulse dose technology deliver oxygen only during inhalation to conserve it and extend battery life, especially in portable models. New devices feature silent operation, digital displays, alarms, connectivity for remote monitoring, and support both pulse and continuous flow modes.

Portable concentrators with long-lasting batteries are popular among active users and travelers, some FAA-approved for flights. IoT integration enables real-time data sharing with healthcare providers, enhancing patient compliance. AI algorithms optimize oxygen delivery based on respiratory patterns. These innovations improve convenience, patient quality of life, and broaden application scope, fueling market growth as adoption increases.

Based on type, the market is divided into portable and stationary oxygen concentrators. In 2024, the portable oxygen concentrator segment holds the largest share of the global oxygen concentrator market. The increasing global geriatric population is a key factor driving demand for portable oxygen concentrators (POCs). Older adults are more vulnerable to chronic respiratory conditions such as COPD, pulmonary fibrosis, and hypoxia related to heart failure. Mobility challenges in old age make POCs a practical solution, allowing elderly patients to receive oxygen therapy without being restricted to a stationary device. Being able to carry oxygen support while moving around at home, outdoors, or during travel greatly improves their independence and quality of life. As the aging population continues to grow-especially in developed areas like North America, Europe, and parts of Asia-the demand for compact, dependable, and easy-to-use oxygen devices like POCs steadily increases, strengthening their market dominance.

Based on end users, the OC market has been categorized into home care settings, hospitals and clinics, and ambulatory surgical centers & physician offices. In 2024, home care settings held the largest share in the OC market. The increasing global elderly population is a key factor driving demand in the home care segment of the oxygen concentrators market. Older adults are more vulnerable to chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), emphysema, and age-related decline in lung function. These conditions often require long-term oxygen therapy, which is increasingly managed at home due to its convenience and lower cost. Additionally, elderly patients often face mobility issues, making frequent hospital visits difficult. Home-based oxygen concentrators provide a safe and accessible solution, allowing independence while maintaining continuous respiratory support. Countries like Japan, Germany, Italy, and the US-with rapidly aging populations-are seeing a particularly high adoption of oxygen concentrators in home care settings.

North America is expected to hold the largest share of the OC market during the forecast period. North America, especially the US and Canada, has highly developed healthcare systems equipped with modern diagnostic and therapeutic technologies. The region's hospitals, clinics, and outpatient centers have widespread access to oxygen delivery equipment, including concentrators. Additionally, structured healthcare policies, integrated insurance networks, and streamlined procurement channels ensure the smooth availability and distribution of these devices. Patients benefit from faster diagnoses and prompt initiation of oxygen therapy. Home care support systems are also advanced, allowing a safe transition from hospital to home with continuous oxygen support. These favorable conditions improve the accessibility and use of oxygen concentrators, especially for chronic patients, and reinforce North America's leadership position in the global oxygen concentrators market.

A breakdown of the primary participants (supply-side) for the oxygen concentrators market referred to in this report is provided below:

• By Company Type: Tier 1:34%, Tier 2: 38%, and Tier 3: 28%
• By Designation: C-level: 26%, Director Level: 35%, and Others: 39%
• By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%

Major players in the oxygen concentrators market include Koninklijke Philips N.V. (Netherlands), Inogen, Inc. (US), Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (China), Caire, Inc. (US), and Drive DeVilbiss Healthcare (US).

Research Coverage

The report assesses the oxygen concentrators market and estimates its size and future growth potential across various segments, including type, technology, flow rate, application, end user, and region. It also provides a competitive analysis of the leading companies in the market, along with their profiles, product offerings, recent developments, and key strategies.

Reasons to Buy the Report

The report will help market leaders and new entrants by providing data on the closest estimates of revenue for the overall oxygen concentrators market and its subsegments. It will aid stakeholders in understanding the competitive landscape and gaining insights to better position their businesses and develop effective go-to-market strategies. Additionally, the report helps stakeholders grasp market trends and offers data on key drivers, obstacles, challenges, and opportunities within the market.

This report provides insights into the following points:

• Analysis of key drivers (rising prevalence of respiratory diseases, growing geriatric population, increasing demand for home healthcare, government initiatives and reimbursement support, technological advancements), restraints (high cost of advanced oxygen concentrators, product recalls or malfunctions), opportunities (integration of digital health features, development of solar-powered or battery-efficient models) and challenges (lack of awareness and diagnosis, competition from low-cost alternatives)
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global OC market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by type, technology, flowrate, application, end user, and region
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global OC market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global OC market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS COVERED
• 1.4 YEARS CONSIDERED
• 1.5 CURRENCY USED
• 1.6 STAKEHOLDERS
• 1.7 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 METHODOLOGY-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OXYGEN CONCENTRATORS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: OXYGEN CONCENTRATORS MARKET, BY TECHNOLOGY AND COUNTRY
• 4.3 OXYGEN CONCENTRATORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 OXYGEN CONCENTRATORS MARKET, REGIONAL MIX
• 4.5 OXYGEN CONCENTRATORS MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing prevalence of chronic respiratory diseases
    • 5.2.1.2 Preference for home-based oxygen therapy
    • 5.2.1.3 Technological advancements in portable oxygen concentrators
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High initial cost and limited reimbursement in some markets
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Expansion in emerging markets
    • 5.2.3.2 Integration with remote monitoring and telehealth
    • 5.2.3.3 Institutional demand and tender-based opportunities
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Operational limitations in remote and power-constrained areas
    • 5.2.4.2 Quality variability and regulatory compliance challenges
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY TYPE
  • 5.4.2 AVERAGE SELLING PRICE TREND OF PORTABLE OXYGEN CONCENTRATORS, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Pressure swing adsorption (PSA) technology
    • 5.9.1.2 Pulse-dose vs. continuous flow delivery
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Remote patient monitoring (RPM) integration
    • 5.9.2.2 Battery and power management systems
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 PSA oxygen plants
    • 5.9.3.2 Oxygen cylinders as backup systems
• 5.10 INDUSTRY TRENDS
  • 5.10.1 RISING DEMAND FOR HOME-BASED OXYGEN THERAPY
  • 5.10.2 INTEGRATION WITH TELEHEALTH AND REMOTE MONITORING
  • 5.10.3 SHIFT TOWARD PORTABLE AND WEARABLE TECHNOLOGIES
  • 5.10.4 CONSOLIDATION AND COMPETITIVE LANDSCAPE EVOLUTION
• 5.11 PATENT ANALYSIS
• 5.12 TRADE ANALYSIS
  • 5.12.1 IMPORT DATA (HS CODE 901920)
  • 5.12.2 EXPORT DATA (HS CODE 901920)
• 5.13 KEY CONFERENCES & EVENTS, 2025-2026
• 5.14 CASE STUDY ANALYSIS
  • 5.14.1 DEPLOYMENT OF PORTABLE OXYGEN CONCENTRATORS IN RURAL INDIA
  • 5.14.2 INOGEN'S DIRECT-TO-CONSUMER EXPANSION IN US
  • 5.14.3 BELLUSCURA'S STRATEGIC PARTNERSHIP WITH CHINESE OEM
• 5.15 REGULATORY ANALYSIS
• 5.16 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.16.1 REGULATORY LANDSCAPE
    • 5.16.1.1 North America
      • 5.16.1.1.1 US
      • 5.16.1.1.2 Canada
    • 5.16.1.2 Europe
      • 5.16.1.2.1 Germany
      • 5.16.1.2.2 France
      • 5.16.1.2.3 UK
    • 5.16.1.3 Asia Pacific
      • 5.16.1.3.1 China
      • 5.16.1.3.2 Japan
      • 5.16.1.3.3 India
    • 5.16.1.4 Latin America
      • 5.16.1.4.1 Brazil
      • 5.16.1.4.2 Mexico
    • 5.16.1.5 Middle East & Africa
      • 5.16.1.5.1 South Africa
      • 5.16.1.5.2 GCC Countries
• 5.17 PORTER'S FIVE FORCES ANALYSIS
  • 5.17.1 THREAT OF NEW ENTRANTS
  • 5.17.2 THREAT OF SUBSTITUTES
  • 5.17.3 BARGAINING POWER OF SUPPLIERS
  • 5.17.4 BARGAINING POWER OF BUYERS
  • 5.17.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.18 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.18.2 BUYING CRITERIA
• 5.19 UNMET NEEDS/END-USER EXPECTATIONS
• 5.20 IMPACT OF 2025 US TARIFF ON OXYGEN CONCENTRATORS MARKET
  • 5.20.1 KEY TARIFF RATES
  • 5.20.2 PRICE IMPACT ANALYSIS
  • 5.20.3 KEY IMPACT ON COUNTRY/REGION
    • 5.20.3.1 US
    • 5.20.3.2 Europe
    • 5.20.3.3 Asia Pacific
  • 5.20.4 IMPACT ON END-USER INDUSTRIES
• 5.21 IMPACT OF ARTIFICIAL INTELLIGENCE ON OXYGEN CONCENTRATORS MARKET
• 5.22 ADJACENT MARKET ANALYSIS

6 OXYGEN CONCENTRATORS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 PORTABLE OXYGEN CONCENTRATORS
• 6.3 STATIONARY OXYGEN CONCENTRATORS

7 OXYGEN CONCENTRATORS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 CONTINUOUS FLOW
• 7.3 PULSE FLOW

8 OXYGEN CONCENTRATORS MARKET, BY FLOWRATE

• 8.1 INTRODUCTION
• 8.2 0-5 L/MIN FLOWRATE
• 8.3 5-10 L/MIN FLOWRATE
• 8.4 ABOVE 10 L/MIN FLOWRATE

9 OXYGEN CONCENTRATORS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 COPD
• 9.3 ASTHMA
• 9.4 RESPIRATORY DISTRESS
• 9.5 OTHER APPLICATIONS

10 OXYGEN CONCENTRATORS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOME CARE SETTINGS
• 10.3 HOSPITALS & CLINICS
• 10.4 AMBULATORY SURGICAL CENTERS & PHYSICIANS' OFFICES

11 OXYGEN CONCENTRATORS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Medicare coverage, COPD prevalence, and connected POCs to catalyze sustained market expansion through 2030
  • 11.2.3 CANADA
    • 11.2.3.1 Provincial funding, COPD burden, and connected POCs to accelerate home oxygen concentrator adoption trajectory
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Strong payer coverage and clinical guidelines to drive predictable replacement cycles in Germany's market
  • 11.3.3 FRANCE
    • 11.3.3.1 Hospital-to-home shift and connected devices sustain resilient replacement cycles in France's oxygen concentrators market
  • 11.3.4 UK
    • 11.3.4.1 Aging population and funded home oxygen programs to underpin steady expansion
  • 11.3.5 ITALY
    • 11.3.5.1 Regional tenders, SSN homecare funding, and COPD burden to support steady growth in Italy's market
  • 11.3.6 SPAIN
    • 11.3.6.1 Driving home-based healthcare with portable oxygen concentrator growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Stable funding and service-led home care models to support steady growth
  • 11.4.3 CHINA
    • 11.4.3.1 Policy momentum and robust manufacturing ecosystem to drive resilient replacement cycles
  • 11.4.4 INDIA
    • 11.4.4.1 Building resilient healthcare infrastructure with rising oxygen concentrator demand
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Hospital-to-home shift and connected POCs to propel South Korea's portable and stationary oxygen concentrator demand growth
  • 11.4.6 AUSTRALIA
    • 11.4.6.1 Policy support, service networks, and digital monitoring to drive steady expansion of Australia's market through 2030
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Public procurement, ANVISA registration, and service networks to drive predictable replacement cycles in Brazil's oxygen therapy landscape
  • 11.5.3 MEXICO
    • 11.5.3.1 Strengthening respiratory care access through expanding oxygen concentrator adoption
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Regional footprint
    • 12.5.5.3 Type footprint
    • 12.5.5.4 Application footprint
    • 12.5.5.5 End User footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs
• 12.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 MnM view
      • 13.1.1.3.1 Right to win
      • 13.1.1.3.2 Strategic choices
      • 13.1.1.3.3 Weaknesses and competitive threats
  • 13.1.2 INOGEN, INC.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches & approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 CAIRE INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches & approvals
      • 13.1.4.3.2 Deals
      • 13.1.4.3.3 Expansions
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 DRIVE DEVILBISS HEALTHCARE
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & approvals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 TEIJIN LIMITED
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
  • 13.1.7 DAIKIN INDUSTRIES, LTD.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
  • 13.1.8 ESAB CORPORATION (GCE GROUP)
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 REACT HEALTH
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Deals
  • 13.1.10 PRECISION MEDICAL, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 NIDEK MEDICAL PRODUCTS, INC.
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
  • 13.1.12 O2 CONCEPTS, LLC
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches & approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 BPL MEDICAL TECHNOLOGIES
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
  • 13.1.14 BESCO
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
  • 13.1.15 OXUS
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
• 13.2 OTHER COMPANIES
  • 13.2.1 FOSHAN KEYHUB ELECTRONIC INDUSTRIES CO., LTD
  • 13.2.2 LONGFIAN SCITECH CO., LTD.
  • 13.2.3 SHENYANG CANTA MEDICAL TECH. CO., LTD.
  • 13.2.4 BELLUSCURA
  • 13.2.5 HOYO SCITECH CO., LTD.
  • 13.2.6 HACENOR SOLUTIONS
  • 13.2.7 XNUO INTERNATIONAL GROUP (USA) HOLDINGS
  • 13.2.8 OXYMED
  • 13.2.9 KALSTEIN
  • 13.2.10 ESS PEE ENTERPRISES

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS